Lowe Syndrome: A Complex Clinical Diagnosis with a Novel Mutation in the OCRL Gene

Abstract

Lowe syndrome (LS) is a rare X-linked condition having a clinical triad of congenital cataracts, intellectual disability, and progressive tubular nephropathy. Although the easily recognizable symptom complex usually evolves by infancy, a unifying diagnosis is often missed. We present a young boy with a prolonged history of multisystem affection, finally leading to the clinical suspicion of LS. The diagnosis was confirmed on genetic analysis as well as a previously unreported mutation in the OCRL gene was discovered. A 9-year-old boy with intellectual disability and recent onset seizures was referred for the evaluation of rickets. In addition, there was a significant past history of neonatal cataracts, infantile glaucoma, persistent albuminuria, and severe short stature with growth hormone deficiency. The characteristic involvement of eyes, brain, and kidneys along with a family history of a maternal uncle being similarly affected led to the clinical suspicion of LS. A whole exome sequencing was performed, which not only confirmed a nonsense mutation, c.2530C > T, in exon 23 of the Lowe gene (OCRL) but also revealed it to be a novel pathogenic variant. This case highlights the importance of piecing together the different facets of a complex clinical syndrome in reaching a challenging diagnosis. Also, LS must be kept as a differential in any child with neonatal cataracts and intellectual disability. Genetic confirmation of LS in our patient partly relieved the parental anxiety, and the child continued to remain under follow-up with multiple specialists, only now with a definite diagnosis.

Keywords

oculocerebrorenal syndrome - rickets - growth hormone deficiency - nonsense mutation

Publikationsverlauf

Eingereicht: 27. November 2020

Angenommen: 18. Januar 2021

Artikel online veröffentlicht:
19. Februar 2021

• References

• 1 Loi M. Lowe syndrome. Orphanet J Rare Dis 2006; 1 (01) 16
• 2 Olivos-Glander IM, Jänne PA, Nussbaum RL. The oculocerebrorenal syndrome gene product is a 105-kD protein localized to the Golgi complex. Am J Hum Genet 1995; 57 (04) 817-823
• 3 Recker F, Reutter H, Ludwig M. Lowe syndrome/Dent-2 disease: a comprehensive review of known and novel aspects. J Pediatr Genet 2013; 2 (02) 53-68
• 4 Lewis RA, Nussbaum RL, Brewer ED. Lowe Syndrome. 2001 Jul 24 [updated 2012 Feb 23]. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP. eds. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2013. Accessed January 31, 2021 at: http://www.ncbi.nlm.nih.gov/books/NBK1480/
• 5 Bökenkamp A, Levtchenko E, Recker F, Ludwig M. Clinical utility gene card for: Lowe syndrome. Eur J Hum Genet 2015; 23 (06) 889
• 6 Bökenkamp A, Ludwig M. The oculocerebrorenal syndrome of Lowe: an update. Pediatr Nephrol 2016; 31 (12) 2201-2212
• 7 Lowe CU, Terrey M, MacLACHLAN EA. Organic-aciduria, decreased renal ammonia production, hydrophthalmos, and mental retardation; a clinical entity. AMA Am J Dis Child 1952; 83 (02) 164-184
• 8 Recker F, Zaniew M, Böckenhauer D. et al. Characterization of 28 novel patients expands the mutational and phenotypic spectrum of Lowe syndrome. Pediatr Nephrol 2015; 30 (06) 931-943
• 9 McSpadden K. Living with Lowe Syndrome: A Guide for Families, Friends and Professionals. Chicago, Ridge: Lowe Syndrome Association Inc.; 2010
• 10 Dai C, Wang L, Li Y. et al. Lowe syndrome with extremely short stature: growth hormone deficiency may be the pathogeny. Growth Factors 2019; 37 (3-4): 170-177
• 11 Hou JW. Amelioration of hypophosphatemic rickets and osteoporosis with pamidronate and growth hormone in Lowe syndrome. J Formos Med Assoc 2009; 108 (09) 730-735
• 12 Zaniew M, Bökenkamp A, Kołbuc M. et al. Long-term renal outcome in children with OCRL mutations: retrospective analysis of a large international cohort. Nephrol Dial Transplant 2018; 33 (01) 85-94
• 13 de Carvalho-Neto A, Ono SE, de Melo Cardoso G, Santos ML, Celidonio I. Oculocerebrorenal syndrome of Lowe: magnetic resonance imaging findings in the first six years of life. Arq Neuropsiquiatr 2009; 67 (2A): 305-307
• 14 Demmer LA, Wippold II FJ, Dowton SB. Periventricular white matter cystic lesions in Lowe (oculocerebrorenal) syndrome. A new MR finding. Pediatr Radiol 1992; 22 (01) 76-77
• 15 Sener RN. Lowe syndrome: proton MR spectroscopy, and diffusion MR imaging. J Neuroradiol 2004; 31 (03) 238-240
• 16 Hichri H, Rendu J, Monnier N. et al. From Lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes. Hum Mutat 2011; 32 (04) 379-388
• 17 Suarez-Artiles L, Perdomo-Ramirez A, Ramos-Trujillo E, Claverie-Martin F. Splicing analysis of exonic OCRL mutations causing Lowe syndrome or dent-2 disease. Genes (Basel) 2018; 9 (01) 15